CR-4056
CR-4056| 식별자 | |
|---|---|
| |
| CAS 번호 | |
| 펍켐 CID | |
| 켐스파이더 | |
| 유니 | |
| 화학 및 물리적 데이터 | |
| 공식 | C17H12N4 |
| 어금질량 | 272.311 g·190−1 |
| 3D 모델(JSmol) | |
| |
| |
CR-4056은 이미다졸린 수용체 I의2 리간드 역할을 하는 새로운 작용 메커니즘을 가진 진통제 후보물질이다.다양한 종류의 신경성 통증에 대한 동물 연구에서 유망한 결과를 보여주었고, 골관절염과 관련된 통증의 잠재적 치료법으로 2단계 인간 임상시험에 도달했다.[1][2][3][4][5]
참조
- ^ Ferrari F, Fiorentino S, Mennuni L, Garofalo P, Letari O, Mandelli S, Giordani A, Lanza M, Caselli G (2011). "Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain". Journal of Pain Research. 4: 111–25. doi:10.2147/JPR.S18353. PMC 3100226. PMID 21647215.
- ^ Li JX, Thorn DA, Qiu Y, Peng BW, Zhang Y (March 2014). "Antihyperalgesic effects of imidazoline I(2) receptor ligands in rat models of inflammatory and neuropathic pain". British Journal of Pharmacology. 171 (6): 1580–90. doi:10.1111/bph.12555. PMC 3954494. PMID 24329196.
- ^ Comi E, Lanza M, Ferrari F, Mauri V, Caselli G, Rovati LC (May 4, 2017). "Efficacy of CR4056, a first-in-class imidazoline-2 analgesic drug, in comparison with naproxen in two rat models of osteoarthritis". Journal of Pain Research. 10: 1033–1043. doi:10.2147/JPR.S132026. PMC 5422496. PMID 28496359.
- ^ Li JX (October 2017). "2 receptors: An update". Pharmacology & Therapeutics. 178: 48–56. doi:10.1016/j.pharmthera.2017.03.009. PMC 5600648. PMID 28322973.
- ^ Rovati LC, Brambilla N, Blicharski T, Probert NJ, Vitalini C, Giacovelli G, Girolami F, D'Amato M (2017). "A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes". Arthritis Rheumatol. 2017 ACR/ARHP Annual Meeting, Abstract 1193. 69 (suppl 10).
{{cite journal}}: CS1 maint : 위치(링크)